Tachykinins mediate a variety of physiological processes in the gastrointes
tinal, pulmonary and genitourinary tract mainly through the stimulation of
NK1 and NK2 receptors. Preclinical evidence obtained through the use of sel
ective tachykinin receptor antagonists indicates that endogenous tachykinin
s are involved in augmented smooth muscle contraction, vasodilatation, chem
otaxis and activation of immune cells, mucus secretion, water absorption/se
cretion. Recent evidence also suggests that endogenous tachykinins released
at the peripheral level may play a role in visceral inflammation, hyperref
lexia and hyperalgesia. Possible mechanisms underlying the stimulation of p
rimary afferent neurons by tachykinins may involve a direct excitation of t
hese neurons and the release of mediators which sensitise or stimulate sens
ory nerves. Tachykinin receptor antagonists could have a clinical utility i
n several human diseases such as irritable bowel syndrome, asthma, and in m
icturition disturbances characterized by a hyperactive bladder (C) 2000 Har
court Publishers Ltd.